New therapies in systemic lupus erythematosus – trials,troubles and tribulations…. working towards a solution

1 Keystone EC  Schiff MH  Kremer JM  . Once weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter randomized, double blind placebo controlled trial. Arthritis Rheum 2004; 50: 353–363.

2 Lipsky PE  van der Heijde DM  St Clair EW  . Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594–1602.

3 Weinblatt ME  Keystone EC  Furst DE  . Adalimumab, a fully human anti-tumour necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35–45.

4 Antoni CE  Kavanaugh A  Kirkham B  . Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis. Arthritis Rheum 2005; 52: 1227–1236.

5 Davis JC  van der Heijde D  Braun J  . Recombinant human tumour necrosis factor receptor (etanercept) for treating ankylosing spondylitis. Arthritis Rheum 2003; 48: 3230–3236.

6 Edwards JC  Szczeparski L  Szechinski J  . Efficiency of B cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572–2581.

7 Cohen SB  Emery P  Greenwald MW  . Rituximab for rheumatoid arthritis refractory to anti-tumour necrosis factor therapy. Arthritis Rheum 2006; 54: 2793–2806.

8 Chan TM  Li FK  Tang CS  . Efficiency of mycophenolate in patients with difuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1156–1162.

9 Ginzler EM  Dooley MA  Aranow C  . Mycophenolate mofetil on intra-venous cyclophophamide for lupus nephritis. N Engl J Med 2005; 353: 2219–2228.

10 Appel GB  Dooley MA  Ginzler EM  . Mycophenolate mofetil compared with intravenous cyclophosphamide as induction therapy for lupus nephritis: Aspreva Lupus Management Study (ALMS) results. 47A of JASN, Vol 18 October 2007.

11 Isenberg DA  Appel GB  Posley MA  . Mycophenolate mofetil compared with intravenous cyclophosphomite an induction for lupus nephritis: ALMS results and BILAG responses. Ann Rheum Dis 2008; 67: S: 53–54.

12 Hay EM  Bacon PA  Gordon C  . The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86: 447–458.

13 Sthoeger ZM  Dayan M  Zinger H  Asher I  Sharabi A  Mozes E  . The toleroganic peptide MCDRI, down regulates pathogenic cytokines and apoptosis and up-regulates. TGF-Bard regulatory T-cells in PBMC of lupus patients. Lupus 2008; 17: 458.

14 Bombardier C  Gladman D  Unowitz MB  . The development and validation of the SLE Disease Activity Index (SLEDAI). Arthritis Rheum 1992; 35: 630–640.

15 Furie R  Stohl W  Ginzler E  . Safety pharmacokinetic and pharmacodynamic results of a Phase 1 single and close escalation study of lymphostatic B (human monoclonal antibody to Bly S) in SLE patients. Arthritis Rheum 2003; 48: S377.

16 Liang MH  Socher SA  Roberts WN  Esdaile JM  . Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum 1988; 31: 817–825.

17 Ramsey-Goldman R  Isenberg DA  . Systemic lupus erythematosus measures. Arthritis Care Res 2003; 49: 5225–5233.

18 Yee CS  Farewell V  Isenberg DA  . British Isles Lupus Assessment Group 2004 Index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 4113–4119.